- The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD
- The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions
- 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects
Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies like Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been ongoing, partly charging what has come to be referred to as the psychedelic renaissance.
Research has so far shown that the drugs – ketamine, psilocybin, MDMA (also known as ecstasy), and LSD – could potentially remedy mental conditions such as post-traumatic stress disorder (“PTSD”), depression, and addiction. There is also growing evidence that psychedelic drugs’ action in the brain differs from addictive drugs’ (https://ibn.fm/ioaZy).
“One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories – opening them evermore to new concepts and states of mind. Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side-effects,” reads an article published in The Guardian (https://ibn.fm/7ihOZ).
In describing this family of promising medicines, Delic Co-founder and CEO Matt Stang similarly highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.” Stang’s comments are contained in a recent announcement in which Delic, a company making a mark in the psychedelic wellness scene, reported the findings of a survey it had commissioned (https://ibn.fm/rV24B).
According to the survey conducted by The Harris Poll, 65% of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine (ketamine, psilocybin, and MDMA) should be made available to patients with treatment-resistant anxiety, depression, or PTSD.
Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings of anxiety, depression, or PTSD. Eighteen percent also said the prescribed drugs worsened their condition or did not improve it at all.
Eighty-three percent of Americans living with anxiety, depression, or PTSD would be open to pursuing alternative treatments proven to be more effective than prescription medication with fewer side effects. More specifically, 66%, 62%, and 56% would be open to pursuing treatment using ketamine, psilocybin, and MDMA, respectively, if each was proven more effective than prescription drugs with fewer side effects.
“We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” added Stang.
The survey was conducted online within the United States in early December among 2,037 adults aged 18 or older, 953 of whom suffer from anxiety/depression/PTSD. It was not based on probability sampling.
Founded in 2018, Delic is a leader in new medicines and treatments for a modern world and is committed to providing education, research, and treatment options to the masses in the field of psychedelics through an umbrella of related businesses that includes the largest chain of psychedelic wellness clinics with Ketamine Wellness Centers (“KWC”) and Ketamine Infusion Centers (“KIC”); media properties Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on the R&D of psilocybin vaporization products; and Meet Delic, the largest psychedelic wellness event.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.